New research uncovers promising new biomarker for aggressiveness of prostate cancer, implications for treatment

October 24, 2012

Research out of Roswell Park Cancer Institute (RPCI) supports the adoption of a new biomarker to measure the aggressiveness of primary prostate tumors. A team of investigators from three institutions, led by Shahriar Koochekpour, MD, PhD, Associate Professor of Cancer Genetics, Urology and Oncology in RPCI's Department of Cancer Genetics, has for the first time produced data showing that levels of serum glutamate, a naturally occurring nonessential amino acid that plays a key role in cancer metabolism, are increased in patients with primary and metastatic prostate cancer.

Collaborators included James L. Mohler, MD, Gissou Azabdaftari, MD, and Kristopher Attwood, PhD, from RPCI; Robert L. Vessella, PhD, from the University of Washington School of Medicine; and Oliver Sartor, MD, from Tulane Cancer Center and the Tulane University School of Medicine. In a study involving 366 men, the team measured serum glutamate levels in 60 healthy adult males, 197 with primary prostate cancer and 109 with metastatic castration-resistant prostate cancer—cancer that progresses following androgen depletion therapy.

"Comparing normal, primary and tissues, we discovered that glutamate receptor is expressed at very high levels in primary and , but at very weak or undetectable levels in benign prostate tissues," notes Dr. Koochekpour. "And serum glutamate was detected at increased levels proportional to , the standard index for rating prostate cancer aggressiveness and prognosis in patients with primary tumors."

The researchers also demonstrated, for the first time, that glutamate deprivation significantly decreases the growth, migration and invasiveness of prostate cancer cell lines, suggesting potential clinical applications. They also report that the glutamate antagonist riluzole (Rilutek), a well-tolerated oral medicine used for mood and anxiety disorders, depression and amyotrophic lateral sclerosis (ALS), induces cell death while inhibiting the progression and motility of human prostate .

"We detected one major difference between African-Americans and Caucasians in the study," Dr. Koochekpour notes. "In African-Americans, serum glutamate levels were higher among those men with metastatic disease than in those with primary prostate cancer, and we didn't see that trend in Caucasian men. This finding may implicate a role for glutamate metabolism in inter-racial disparities of prostate cancer."

Dr. Koochekpour and colleagues are currently conducting a preclinical study assessing the effectiveness of riluzole in preventing growth of human prostate cancer cells in animal models, and hope to build on these results in the clinical setting within the next 12-18 months. The paper, "Serum Glutamate Levels Correlate with Gleason Score and Glutamate Blockade Decreases Proliferation, Migration, and Invasion and Induces Apoptosis in Prostate Cancer Cells," was published October 16 in Clinical Cancer Research and can be accessed at clincancerres.aacrjournals.org … 078-0432.CCR-12-1308.

Explore further: Study identifies new prostate cancer drug target

Related Stories

Study identifies new prostate cancer drug target

February 6, 2012
Research led by Wanguo Liu, PhD, Associate Professor of Genetics at LSU Health Sciences Center New Orleans, has identified a new protein critical to the development and growth of prostate cancer. The findings are published ...

Scientists identify new mechanism of prostate cancer cell metabolism

March 22, 2012
Cancer cell metabolism may present a new target for therapy as scientists have uncovered a possible gene that leads to greater growth of prostate cancer cells.

Recommended for you

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22, 2017
Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study ...

One in four U.S. seniors with cancer has had it before

November 22, 2017
(HealthDay)—For a quarter of American seniors, a cancer diagnosis signals the return of an old foe, new research shows.

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...

Researchers discover specific tumor environment that triggers cells to metastasize

November 21, 2017
A team of bioengineers and bioinformaticians at the University of California San Diego have discovered how the environment surrounding a tumor can trigger metastatic behavior in cancer cells. Specifically, when tumor cells ...

New study points the way to therapy for rare cancer that targets the young

November 21, 2017
After years of rigorous research, a team of scientists has identified the genetic engine that drives a rare form of liver cancer. The findings offer prime targets for drugs to treat the usually lethal disease, fibrolamellar ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.